PipelineReview.com2h
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan I October 9, 2024 I Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a ...
PipelineReview.com3h
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, CA, USA I October 8, 2024 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
PipelineReview.com3h
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...
PipelineReview.com3h
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data
OXFORD, UK I October 8, 2024 I Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced ...
PipelineReview.com3h
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines ...
PipelineReview.com1d
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, MA, USA I October 07, 2024 I Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for ...
PipelineReview.com1d
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 I Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
PipelineReview.com1d
New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients ...
PipelineReview.com1d
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s ...
PipelineReview.com1d
Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
LUND, Sweden I October 7, 2024 I Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month ...
PipelineReview.com1d
FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer
The CTA submission follows strong clinical topline data for FG001 tested in a proof-of-concept phase II clinical trial in patients with head and neck cancer and is a step on the path to the patients ...
PipelineReview.com1d
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy
This open-label, global, multi-center Phase Ib clinical study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of this combination regimen in ES-SCLC patients. Both ...